Penumbra (PEN) Capital Expenditures Growth (3y) (2017 - 2026)
Penumbra (PEN) Capital Expenditures Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 10.17% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | 1.81% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 10.35% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 2.15% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 0.84% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 8.08% |
| 10 | Penumbra | 12.51 Bn | 11.90 Bn | 253.41 Mn | 51.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.99% |
| Dec 31, 2025 | 1.67% |
| Sep 30, 2025 | -85.00% |
| Jun 30, 2025 | 52.06% |
| Mar 31, 2025 | 39.54% |
| Dec 31, 2024 | -41.81% |
| Sep 30, 2024 | 27.94% |
| Jun 30, 2024 | 343.50% |
| Mar 31, 2024 | 38.67% |
| Dec 31, 2023 | -355.36% |
| Sep 30, 2023 | 38.53% |
| Jun 30, 2023 | -33.16% |
| Mar 31, 2023 | -27.29% |
| Dec 31, 2022 | 447.27% |
| Sep 30, 2022 | 57.17% |
| Jun 30, 2022 | 117.61% |
| Mar 31, 2022 | 79.30% |
| Dec 31, 2021 | 268.21% |
| Sep 30, 2021 | 117.78% |
| Jun 30, 2021 | -57.94% |